Europe Omega 3 Market By Type, By Application, By Source, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

The Europe Omega 3 Market is expected to witness market growth of 6.6% CAGR during the forecast period (2021-2027).

Omega-3 fatty acids may help with bone and joint health. In a pilot trial of calcium-deficient women, it was discovered that EPA combined with calcium supplements strengthened bones more effectively than calcium supplements alone. This finding implies that omega-3 fatty acids are good for bone health. Furthermore, studies have demonstrated the benefit of omega-3 ingestion in alleviating arthritis symptoms.

Additionally, DHA is a major component of the retina, which is the eye's innermost layer of tissue. DHA has been shown to protect adult eyes against macular degeneration, in studies. Macular degeneration is a type of visual loss that causes hazy vision over time. Omega-3 consumption and eye health have a positive connection, implying that omega-3s may protect against the pathophysiology of eye illnesses.

The growing demand for omega 3 supplements in Europe can be ascribed to an ageing population and an increase in cases of various health disorders, notably in economies such as Germany, France, the Netherlands, and the United Kingdom. With the rise in the cases of various CVDs and mental illness across various nations of the region, the demand for various supplements including omega-3 is expected to witness a rise in the coming years.

The Germany market dominated the Europe Omega 3 Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $201.3 million by 2027. The UK market is expected to witness a CAGR of 5.8% during (2021 - 2027). Additionally, The France market is anticipated to grow a CAGR of 7.4% during (2021 - 2027).

Based on Type, the market is segmented into Docosahexaenoic acid (DHA), Eicosapentaenoic acid (EPA), and Alpha-linolenic acid (ALA). Based on Application, the market is segmented into Supplements & Functional Foods, Pharmaceuticals, Infant Formula, Animal Feed & Pet Food and Others. Based on Source, the market is segmented into Marine Source and Plant Source. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Aker BioMarine AS, GC Rieber VivoMega AS (GC Rieber group), Epax Norway AS (Pelagia Holding AS), FMC Corporation, BASF SE, Koninklijke DSM N.V., Lonza Group AG, Orkla ASA (Orkla Health), Croda International PLC, and Omega Protein Corporation (Cooke, Inc.).

Scope of the Study

Market Segments Covered in the Report:

By Type

• Docosahexaenoic acid (DHA)
• Eicosapentaenoic acid (EPA), and
• Alpha-linolenic acid (ALA)

By Application

• Supplements & Functional Foods
• Pharmaceuticals
• Infant Formula
• Animal Feed & Pet Food and
• Others

By Source

• Marine Source and
• Plant Source

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Aker BioMarine AS
• GC Rieber VivoMega AS (GC Rieber group)
• Epax Norway AS (Pelagia Holding AS)
• FMC Corporation
• BASF SE
• Koninklijke DSM N.V.
• Lonza Group AG
• Orkla ASA (Orkla Health)
• Croda International PLC
• Omega Protein Corporation (Cooke, Inc.)

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free